The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study

Claudio Jommi (), Patrizio Armeni, Margherita Battista, Paolo Procolo, Giuseppe Conte, Claudio Ronco, Mario Cozzolino, Anna Maria Costanzo, Umberto Luzio Paparatti, Gabriella Concas and Giuseppe Remuzzi
Additional contact information
Claudio Jommi: Università del Piemonte Orientale
Patrizio Armeni: SDA School of Management Bocconi
Margherita Battista: Università del Piemonte Orientale
Paolo Procolo: Università del Piemonte Orientale
Giuseppe Conte: Second University of Naples
Claudio Ronco: San Bortolo Hospital
Mario Cozzolino: University of Milan
Anna Maria Costanzo: Abbvie Srl, Campoverde di Aprilia
Umberto Luzio Paparatti: Abbvie Srl, Campoverde di Aprilia
Gabriella Concas: Struttura Complessa Territoriale Nefrologia e Dialisi-ASL 8 Cagliari
Giuseppe Remuzzi: IRCCS, Istituto di Ricerche Farmacologiche Mario Negri

PharmacoEconomics - Open, 2018, vol. 2, issue 4, No 12, 459-467

Abstract: Abstract Background Chronic kidney disease (CKD) is an important public health problem. Most of the evidence on its costs relates to patients receiving dialysis or kidney transplants, which shows that, in these phases, CKD poses a high burden to payers. Less evidence is available on the costs of the predialytic phase. Objective The aim of this study was to estimate the annual cost of patients with CKD not receiving dialysis treatment, using the Italian healthcare system perspective and a prospective approach. Methods A 3-year observational study (December 2010–September 2014) was carried out to collect data on resource consumption for 864 patients with CKD. Costs were estimated for both patients who completed the follow-up and dropouts. Results The mean annual total (healthcare) cost per patient equalled €2723 (95% confidence interval 2463.0–2983.3). Disease severity (higher CKD stage), multiple comorbidities, dropout status and belonging to the southern region are predictive of higher costs. Pharmaceuticals, hospitalisation, and outpatient services account for 71.5, 18.8 and 9.7% of total healthcare expenditure, respectively. Recent estimates of Italian costs of patients receiving dialysis are nine times the unit costs of CKD for patients estimated in this study. Unit costs at stage 5 CKD (the highest level of severity) equals 4.7 times the costs for patients at stage 1 CKD. Conclusion Despite its limitations, this study provides further evidence on the opportunity to invest in the first phases of CKD to avoid progression and an increase in healthcare costs.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0062-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-017-0062-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0062-z

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().